A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
Clinical trial NCT04826406 · UNKNOWN
Trial details
- NCT number
- NCT04826406
- Sponsor
- Hunan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-03
- Primary completion
- 2022-03-02
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.